Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2041 |
PD153035
NSC 669364,SU-5271,ZM 252868,AG1517 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PD153035 (NSC-669364) 是一种EGFR 抑制剂,Ki 和IC50值分别为6和25 pM。 | |||
T1761 |
PD153035 hydrochloride
ZM 252868 HCl,AG 1517,Tyrphostin AG 1517,SU 5271,PD153035 HCl,ZM 252868 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PD153035 hydrochloride (ZM 252868) 是有效地EGFR 抑制剂,Ki 和IC50值分别为6和25 pM。 | |||
T69055 |
PD153035 nitrate
|
Others | Others |
PD153035 is a ATP-competitive EGFR inhibitor with an IC50 and Ki of 25 and 6 pM. PD153035 effectively blocks the enhancement of mitogenesis, induction of early gene expression, and oncogenic transformation that occur in response to EGF receptor stimulation. With human fibroblasts and epidermoid carcinoma cells, PD153035 at nanomolar concentrations rapidly inhibits EGFR autophosphorylation. With breast and ovarian cancer cells, PD153035 not only blocks cell growth via inhibition of EGFR, but also... | |||
T69985 |
Lifirafenib HCl
|
Others | Others |
Lifirafenib, also known as Beigene-283, is a Novel potent and selective RAF Kinase and EGFR inhibitor. BGB-283-displays Potent Antitumor Activity in B-RAF Mutated Colorectal Cancers. In vitro, BGB-283 potently inhibits B-RAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harbouring B-RAFV600E and EGFR mutation/amplification. In B-RAFV600E CRC cell lines, BGB-283 effectively inhibits the ... | |||
T3558 |
EBE-A22
PD153035 Analog 63 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EBE-A22 (PD153035 Analog 63) 是 PD153035 衍生物,PD153035 能够抑制 ErbB-1 磷酸化,但对 EBE-A22 则无抑制作用。 |